ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

GENEVA, Nov. 23, 2015 (GLOBE NEWSWIRE) -- ObsEva , a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, today announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing. The financing included new investors HBM Healthcare Investments, New Enterprise Associates (NEA), OrbiMed, Rock Springs Capital as well as existing investors Sofinnova Partners, which seeded the company, Sofinnova Ventures, Novo Ventures and MS Ventures. In conjunction with the financing, Ed Mathers from NEA will join ObsEva's Board of Directors. The proceeds will support continued progress in ObsEva's late-stage pipeline of novel, oral treatments for women's reproductive health conditions.

" This significant financing and the quality of the investors affirm that ObsEva is leading the field through our development expertise in high-value, oral treatments for endometriosis, infertility and preterm labor, " said ObsEva CEO & Co-Founder, Ernest Loumaye, MD, PhD. " We welcome the new investors and look forward to benefiting from their insights and expertise as we continue our commitment to develop novel drugs addressing women's reproductive health ."

ObsEva has achieved substantial pipeline development in 2015. The company's product candidate OBE001, an oral oxytocin antagonist, is currently in Phase 2 for preterm labor and a separate Phase 2 study for assisted reproductive technology (ART). OBE002, a first-in-class, oral PGF2α receptor antagonist for preterm labor, will enter the clinic in 2016. ObsEva recently announced the expansion of its pipeline through an exclusive license with Kissei Pharmaceutical Co., Ltd. for OBE2109, an oral gonadotropin-releasing hormone (GnRH) antagonist for endometriosis that recently completed three Phase 2a studies in Japan.

Leerink Partners LLC acted as the exclusive financial advisor for the financing.

About ObsEva's Pipeline

ObsEva is advancing a robust pipeline of oral, late-stage compounds to treat women's reproductive health conditions from conception to birth.

OBE001 is an oral, new generation oxytocin antagonist. Oxytocin antagonists are potent inhibitors of uterine contractions. OBE001 is being developed for oral treatment of preterm labor, between 32 to 36 weeks of gestation, and a Phase 2 study of OBE001 Versus Placebo in the Delay of Preterm Birth (TERM) is ongoing. OBE001 is also currently being assessed in a separate Phase 2 clinical study for assisted reproductive technology (ART) through improving embryo implantation and clinical pregnancy rates in women undergoing in vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI).

OBE002 is a first-in-class, orally active, small molecule PGF2α receptor antagonist. Inhibition of the PGF2α receptor is a new modality for treating preterm labor as it has the potential not only to suppress uterine contractility but also to prevent cervical changes resulting from preterm labor, and to inhibit inflammation. A Phase 1 study of OBE002 is scheduled to start mid-2016.

OBE2109 (developed in Asia by Kissei Pharmaceutical Co., Ltd. as KLH-2109) is a novel, oral GnRH antagonist that prevents the endogenous gonadotropin releasing hormone (GnRH) from activating its pituitary receptors which ultimately reduces estrogen production by the ovaries. OBE2109 is in development for endometriosis and has a potentially best-in-class profile that allows partial estrogen suppression. It maintains estradiol in the low-normal range, providing symptom reduction while avoiding significant bone loss or other adverse effects that can be associated with excessive suppression of estrogen. Phase 2a studies in Japan indicate that KLH-2109 induces a dose-dependent reduction in serum LH and estradiol, resulting in a reduction of endometriosis-associated pain and bleeding days. A Phase 2b study of OBE2109 versus Placebo in endometriosis is scheduled to start mid-2016.

About ObsEva

ObsEva is a clinical stage biopharmaceutical company focusing on the development of a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth. Our lead programs target the underserved problems of endometriosis, infertility and preterm labor affecting more and more women worldwide. The ObsEva team's unique development expertise is supported by top-tier investors in order to build a leading company in pregnancy pharmaceuticals. www.ObsEva.com

Press release (PDF)

MEDIA CONTACT Gretchen Schweitzer or Blair Atkinson MacDougall Biomedical Communications Direct: +49 172 861 8540 or +1 812 454 6257 Main: +49 89 2424 3494 or +1 781 235 3060 CONTACT INFORMATION ObsEva CEO Office Delphine Renaud +41 22 552 1550

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 171

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 90

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 25

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 95

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 234

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 148

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Algeness® VL Filler Receives Marketing Approval in China

Updated Category News Views 273

Exciting Developments for Advanced Aesthetic Technologies Advanced Aesthetic Technologies, Inc. (AAT) recently celebrated a significant milestone with the approval of their Algeness® VL agarose facial injection filler for marketing in China. This landmark achievement opens up new avenues for AAT in expanding their product offerings in the Asian market and showcases their...

Continue Reading
Criminal Charges Anticipated in Trump Campaign Hacking Case

Updated Category News Views 154

Criminal Charges Expected in Trump Campaign Hacking Case U.S. authorities are preparing to file criminal charges regarding an incident in which the Trump campaign claimed its internal communications were hacked, allegedly by the Iranian government. This concerning situation has drawn the attention of both the public and officials, raising serious issues surrounding...

Continue Reading
Semler Scientific Faces Class Action Lawsuit: What Investors Need to Know

Updated Category News Views 187

Semler Scientific and the Class Action Lawsuit Overview In recent news, a class action lawsuit has taken center stage involving Semler Scientific, Inc. (SMLR). Investors who have experienced losses related to their investments in Semler are advised to take note of this development, which may directly impact their financial outcomes. Understanding the Lawsuit This class...

Continue Reading
FTC Solar Engages Investors at Key Industry Conferences

Updated Category News Views 159

FTC Solar Engages Investors at Key Industry Conferences FTC Solar, Inc. (Nasdaq: FTCI), an innovative leader in solar tracker systems and engineering services, is set to make significant strides in connecting with investors at three prominent conferences. These events provide a platform for the management team, including CEO Yann Brandt, to engage in discussions that...

Continue Reading
Anixa Biosciences Set to Share Innovations in Cancer Therapy

Updated Category News Views 88

Anixa Biosciences Set to Conduct a Notable Presentation Anixa Biosciences, Inc. (NASDAQ: ANIX), a leading biotechnology firm dedicated to the treatment and prevention of cancer, has taken a significant step forward by announcing its participation in a prestigious investment conference. This event, the H.C. Wainwright 27th Annual Global Investment Conference, promises to...

Continue Reading